BBIO
BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) has 17 SEC Form 4 filings (36 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 13, 2026.
The most active filer is Director Cook Jennifer E. with 4 filings. Insiders have net sold $25.5M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Neil Kumar
- Employees:725
- HQ:Palo Alto, CA, US
- IPO:2019-06-27
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$25.5M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Market Cap
$15.7B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Ellis AndreaFirst filing | Director | Sale | 17,167 | $1.4M | Jul 13 | SEC ↗ |
| Director | Sale | 148,589 | $13.2M | Jul 13 | SEC ↗ | |
| Director | Sale | 2,196 | $151K | Jun 24 | SEC ↗ | |
| Director | Sale | 37,167 | $2.6M | Jun 24 | SEC ↗ | |
| Director | Sale | 2,808 | $191K | Jun 24 | SEC ↗ | |
| Director | Sale | 2,196 | $151K | Jun 24 | SEC ↗ | |
Cook Jennifer E.First filing | Director | Sale | 90,240 | $6.0M | Jun 17 | SEC ↗ |
Kumar NeilFirst filing | Chief Executive Officer | Sale | 26,103 | $1.8M | May 26 | SEC ↗ |
Congress trading BBIO
See timeline →- DRep. Gilbert CisnerosPurchase$1,001 - $15,0002026-05-11
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Related companies
BridgeBio Pharma, Inc. is in the Healthcare sector.